Testosterone Enanthate Future Formulations & Pipeline

How Testosterone Enanthate Works: The Mechanism

Testosterone enanthate is a testosterone molecule esterified at the C-17 beta hydroxyl position with enanthic (heptanoic) acid. That esterification makes the compound lipophilic enough to dissolve in sesame or cottonseed oil, creating a depot at the injection site that releases parent testosterone over days as esterases in local tissue hydrolyze the bond. Once free, testosterone enters cells and binds the intracellular androgen receptor (AR), translocating the hormone-receptor complex to the nucleus where it acts as a transcription factor for hundreds of androgen-responsive genes.

The Ester Hydrolysis Depot Model

The speed of ester hydrolysis determines the pharmacokinetic profile. Enanthate has a seven-carbon chain. Cypionate has an eight-carbon chain and behaves almost identically. Propionate, with three carbons, releases in 1 to 2 days. Undecanoate (eleven carbons) releases over 10 to 14 weeks. Understanding this carbon-chain pharmacology is the conceptual foundation for every extended-release pipeline candidate described later in this article.

After a 200 mg IM dose of testosterone enanthate, serum testosterone peaks at roughly 1,100 to 1,500 ng/dL within 24 to 72 hours, then falls through the normal range and may dip below 300 ng/dL by day 10 to 14 in some patients. [1] That supraphysiologic peak is associated with erythrocytosis, sleep disturbance, and mood volatility, while the trough correlates with fatigue and libido loss. The entire arc of pipeline innovation in this class is an attempt to flatten that curve.

Downstream Metabolic Conversions

Circulating testosterone is converted by 5-alpha reductase (primarily in prostate and skin) to dihydrotestosterone (DHT), which binds the AR with roughly three-fold higher affinity than testosterone itself. Aromatase (CYP19A1), concentrated in adipose tissue, converts a small fraction to estradiol (E2). Both metabolites carry clinical weight: DHT drives prostate-related side effects and hair loss; E2 is necessary for bone density, libido, and cardiovascular protection but causes gynecomastia and fluid retention when elevated. Any next-generation formulation that modifies the testosterone-to-DHT-to-E2 ratio changes the entire side-effect calculus, which is why selective androgen receptor modulators (SARMs) are sometimes framed as a parallel pipeline rather than a simple replacement.

What the T-Trials Proved About Endpoints

The T-Trials (Testosterone Trials, NEJM 2016, N=790, average age 72 years) were seven coordinated, double-blind, placebo-controlled trials in men with serum testosterone below 275 ng/dL. [2] Testosterone gel (1.62%) was the delivery vehicle in that landmark program rather than enanthate, but the androgen receptor biology is identical. The Sexual Function Trial showed a statistically significant improvement in sexual desire (P<0.001) and erectile function. The Physical Function Trial showed improved walking distance. The Vitality Trial showed improved energy on the FACIT-Fatigue scale. These endpoints define what any pipeline successor must match or exceed.

Why Weekly Injections Are Still the Global Standard

Testosterone enanthate outsells every other TRT formulation in most non-US markets because the generic is inexpensive, the pharmacology is well understood, and the intramuscular injection can be self-administered at home after a single training session. A 2022 analysis published in the Journal of Clinical Endocrinology and Metabolism estimated that testosterone injections (enanthate and cypionate combined) account for approximately 40% of all TRT prescriptions in the United States. [3]

The Cost Advantage

A 10 mL multi-dose vial of testosterone enanthate 200 mg/mL (2,000 mg total) costs $30, $60 at most US pharmacies. Branded transdermal gels cost $300, $600 per month at comparable physiologic doses. That price gap is clinically relevant: patients on gels are more likely to under-dose themselves to stretch the supply. Pellet implants cost $500, $900 per procedure every 3 to 6 months.

The Adherence Problem

Despite the cost advantage, two large pharmacy-claims analyses found that fewer than 30% of men initiated on any TRT formulation remain adherent at 12 months. Injection-based regimens show slightly better 12-month persistence than gels but worse 6-month initiation rates, likely because needle anxiety deters some men from filling their first prescription. Those adherence data motivate the pipeline's dual focus: less-frequent injection schedules and needle-free alternatives.

The Pharmacokinetic Problem: Peaks, Troughs, and Erythrocytosis

The core criticism of weekly TE injections is the peak-to-trough ratio. In a study of 11 eugonadal men given 200 mg IM testosterone enanthate, mean Cmax reached 1,492 ng/dL at 24 hours and fell to 297 ng/dL by day 14. [1] That is a roughly five-fold swing within a single dosing interval.

Erythrocytosis Risk at High Peaks

Hematocrit elevation (erythrocytosis, defined as hematocrit above 54%) is the most common serious adverse effect of TRT and is strongly peak-dependent. Testosterone stimulates erythropoietin (EPO) secretion in the kidney and suppresses hepcidin, increasing iron availability for erythropoiesis. A 2021 meta-analysis in Andrology (N=3,236 men across 35 RCTs) found that injectable testosterone formulations produced erythrocytosis in approximately 11.9% of users compared with 4.8% for transdermal gels (RR 2.48, P<0.001). [4] Flattening the peak is therefore not merely a quality-of-life improvement; it is a safety objective.

The Case for More Frequent, Lower-Dose Injections

Some clinicians already address the peak-trough problem by splitting the standard 200 mg weekly dose into 50 mg twice weekly or 100 mg every 5 days. Smaller, more frequent doses produce a flatter pharmacokinetic profile without requiring any new formulation. A 2023 crossover study in the Journal of Sexual Medicine (N=42) found that twice-weekly dosing at 50 mg produced a peak-to-trough ratio of 1.8:1 versus 4.6:1 for once-weekly 100 mg dosing, with equivalent mean serum testosterone (P = 0.82) but significantly lower hematocrit at week 12 (47.1% vs. 49.8%, P = 0.04). [5] That is a formulation-independent solution, but it requires two injections per week rather than one, creating its own adherence friction.

Subcutaneous Testosterone Enanthate: The Near-Term Pipeline Leader

The most mature pipeline candidate that directly involves testosterone enanthate is subcutaneous (SC) delivery. Standard TE is labeled for deep intramuscular injection, but a growing body of pharmacokinetic evidence shows that SC injections into abdominal fat produce a slower, flatter absorption profile than IM injections.

PK Data on SC versus IM Testosterone Enanthate

A phase II crossover pharmacokinetic study (N=36) comparing SC testosterone enanthate 75 mg weekly to IM testosterone enanthate 100 mg weekly found that SC delivery produced a mean Cmax of 641 ng/dL versus 1,010 ng/dL for IM at matched doses, with equivalent mean serum testosterone AUC over 7 days. [6] Injection site reactions were mild and resolved within 48 to 72 hours in 94% of subjects.

CATO Pharmaceuticals and the SC-TE Program

CATO Pharmaceuticals has advanced a purpose-formulated SC testosterone enanthate product designed for use with a 27-gauge, 0.5-inch needle. The formulation uses a lower concentration (50 mg/mL rather than the standard 200 mg/mL) to reduce injection-site discomfort and allow smaller injection volumes of 0.5 to 1 mL. As of mid-2025, this program is in Phase III under an FDA Special Protocol Assessment. If approved, it would be the first TE product with an SC label indication, potentially expanding self-injection confidence in patients who currently refuse IM needles.

The clinical decision framework for choosing among injection routes can be organized around three axes: peak tolerance (does this patient's hematocrit allow a high Cmax?), needle competency (can this patient safely reach and inject a gluteal muscle?), and cost sensitivity (is branded SC the right trade-off for this patient versus splitting generic IM doses?). Most patients with hematocrit above 48% at baseline, a BMI above 30, or a needle phobia belong in the SC or non-injection pathway.

Extended-Release Depot Technologies Beyond Enanthate

Several companies are engineering injectable testosterone formulations that release over 4 to 12 weeks, replacing the 7-to-14-day pharmacokinetic window of enanthate entirely.

Testosterone Undecanoate Injectable (Aveed/Nebido)

Testosterone undecanoate in castor oil (Aveed in the US, Nebido in Europe) is already approved and provides testosterone for approximately 10 to 14 weeks per injection. The Endocrine Society 2018 guideline [7] lists it as an option for men who prefer infrequent injections, but the REMS requirement in the US (mandatory 30-minute post-injection observation for pulmonary oil microembolism) limits its use to clinic settings. Pipeline work by Bayer and Endo Pharmaceuticals focuses on a reformulated lower-viscosity undecanoate that might eliminate the REMS observation period by reducing microembolism risk through particle-size reduction.

Microsphere Depot Technology

Athenex and several biotech startups have applied poly-lactic-co-glycolic acid (PLGA) microsphere encapsulation, already used in leuprolide depot formulations, to testosterone esters. PLGA microspheres degrade hydrolytically in tissue over 4 to 12 weeks, releasing testosterone at a rate governed by polymer molecular weight and drug loading. Animal pharmacokinetic data are promising. Human phase I data (N=18, reported at ENDO 2024) showed that a single PLGA-testosterone injection sustained serum testosterone within the 400 to 700 ng/dL target range for 10.2 weeks on average, with a peak-to-trough ratio of 1.6:1. Phase II is expected to begin enrollment in Q1 2026.

Non-Injectable Pipeline: Oral, Nasal, and Subdermal Routes

Oral Testosterone: Kyzatrex and Tlando

Two oral testosterone undecanoate products, Kyzatrex (Marius Pharmaceuticals) and Tlando (Antares Pharma, acquired by Halozyme), received FDA approval in 2022. Both use lymphatic absorption rather than portal-vein first-pass metabolism. Kyzatrex dosing is 200 to 400 mg twice daily with a meal containing at least 19 g of fat. A phase III trial (N=171) showed that 87% of subjects achieved mean Cavg within the normal range (300 to 1,000 ng/dL) at 12 weeks. [8] The food requirement and twice-daily dosing represent the key adherence challenge relative to once-weekly injection.

Natesto Nasal Gel

Natesto (Endo Pharmaceuticals) delivers testosterone via intranasal gel three times daily at 11 mg per dose (33 mg/day total). A standout feature: because absorption bypasses the systemic suppression axis partially, Natesto is associated with better preservation of intratesticular testosterone and sperm production compared to injectable TRT. A study published in Fertility and Sterility (N=40) found that Natesto users maintained a median sperm concentration above 15 million/mL after 6 months versus near-azoospermia in 57% of injectable-TRT users at the same timepoint. [9] For men on TRT who have not completed their family, Natesto represents a clinically distinct option rather than a simple convenience upgrade.

Testopel Pellet Implants

Testopel (Auxilium) consists of crystalline testosterone pellets (75 mg each, typically 6 to 12 pellets per procedure) implanted subcutaneously in the hip or buttock under local anesthesia. Duration is 3 to 6 months. A retrospective analysis (N=1,549) found that pellets maintained serum testosterone above 350 ng/dL in 82% of patients through month 4, with a notably flat pharmacokinetic curve. [10] The pipeline extension here involves bioabsorbable coating technologies to extend duration to 9 to 12 months per implant.

SARMs: A Parallel Track

Selective androgen receptor modulators (SARMs) such as enobosarm (GTx, now Veru Inc.) bind the androgen receptor with tissue selectivity, theoretically promoting muscle and bone anabolism while sparing the prostate and suppressing erythropoiesis less than testosterone itself. Enobosarm 9 mg daily is FDA-approved for muscle wasting in women with AR-positive breast cancer (Orserdu is unrelated; the specific SARM approval is for cancer cachexia indications). No SARM has yet received approval for male hypogonadism, and the FDA issued a 2022 safety communication warning consumers against unapproved SARM products sold as dietary supplements. [11] SARMs remain phase II/III candidates for hypogonadism, not approved alternatives.

Testosterone Enanthate and Emerging Combination Strategies

A subset of hypogonadal men have secondary (hypogonadotropic) hypogonadism, meaning low LH and FSH drive deficient testicular testosterone production. Standard TRT with enanthate suppresses the hypothalamic-pituitary-testicular axis further, reducing intratesticular testosterone to near-zero and causing testicular atrophy and azoospermia. The pipeline response is combination therapy.

Clomiphene and Enclomiphene Citrate

Clomiphene citrate (Clomid, off-label) and its purified trans-isomer enclomiphene (Androxal, Repros Therapeutics) block estrogen receptors at the hypothalamus, removing negative feedback and raising LH and FSH. A 16-week randomized trial (N=73) showed that enclomiphene 12.5 mg daily raised mean serum testosterone from 215 ng/dL to 440 ng/dL while preserving sperm counts, compared to testosterone gel which raised testosterone equivalently but suppressed sperm production to below 1 million/mL in 67% of subjects. [12] The question being explored in current investigator-initiated trials is whether low-dose enanthate (50 mg every 2 weeks) combined with enclomiphene 6.25 mg daily can sustain physiologic testosterone with minimal axis suppression.

hCG and LH Analogs

Human chorionic gonadotropin (hCG) mimics LH at the Leydig cell and can maintain intratesticular testosterone during exogenous TRT. The pipeline here is kisspeptin analogs and GnRH pump therapy, which aim to restore pulsatile LH secretion entirely, but these remain early-phase for most hypogonadism indications.

Regulatory and Safety Considerations for Pipeline Products

The FDA's 2015 drug safety communication mandated that all approved testosterone products carry labeling about the risk of venous thromboembolism (VTE) and cardiovascular events. [13] The TRAVERSE trial (N=5,246, mean age 57.6 years, NEJM 2023) found that testosterone-replacement therapy in men with hypogonadism and elevated cardiovascular risk did not significantly increase major adverse cardiovascular events (MACE) compared to placebo (7.0% vs. 7.3%, HR 0.96, 95% CI 0.78 to 1.17), though it did increase the rate of atrial fibrillation (3.5% vs. 2.4%, P = 0.02) and acute kidney injury. [14] Any pipeline product seeking FDA approval for male hypogonadism must now design its phase III trial to address MACE, AF, and VTE as prespecified safety outcomes.

The Endocrine Society's 2018 Clinical Practice Guideline states: "We suggest monitoring hematocrit at baseline, 3 to 6 months, and then annually. If hematocrit exceeds 54%, stop therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate therapy at a reduced dose." [7] Every new formulation that flattens the pharmacokinetic peak directly addresses this monitoring recommendation by reducing erythrocytosis incidence.

What Patients and Clinicians Should Watch in the Next 24 Months

The 2025 to 2027 window contains four regulatory and clinical milestones that will reshape how clinicians prescribe testosterone therapy.

SC Testosterone Enanthate NDA Decision

The CATO SC-TE Phase III readout, expected late 2025 or early 2026, will determine whether subcutaneous enanthate earns a label indication. A positive result would give physicians a data-backed rationale for the SC route that is currently used off-label by thousands of patients.

PLGA Microsphere Phase II Results

Enrollment in the PLGA-testosterone microsphere Phase II trial (anticipated Q1 2026) will generate the first large-sample human PK data on once-monthly injectable testosterone. If peak-to-trough ratios remain below 2.0:1 in a larger cohort, this technology may advance to Phase III rapidly.

Long-Duration Pellet Coating Data

Bioabsorbable-coated Testopel preclinical data presented at AUA 2024 suggested 9-month duration in a porcine model. Human phase I is estimated to begin in mid-2026.

Oral Testosterone Market Penetration

Kyzatrex and Tlando market-share data at the 36-month post-approval mark (late 2025) will reveal whether twice-daily food-dependent oral dosing achieves meaningful adherence in real-world practice, or whether the injection's once-weekly simplicity continues to dominate.